AI Article Synopsis

  • In the absence of direct comparisons, researchers used unanchored matching-adjusted indirect comparisons to evaluate the effectiveness of zanubrutinib against ibrutinib and rituximab in patients with relapsed or refractory marginal zone lymphoma (MZL).
  • They applied logistic propensity score models to align patient data from two phase II trials with aggregate data from larger studies involving ibrutinib and rituximab, focusing on factors like previous treatments, MZL subtype, and patient age.
  • Results indicated that zanubrutinib provided significant improvements in overall response and progression-free survival compared to both ibrutinib and rituximab for patients with previously treated MZL.

Article Abstract

In the absence of head-to-head randomized trials, unanchored matching-adjusted indirect comparisons were conducted to estimate the relative efficacy of zanubrutinib versus ibrutinib and zanubrutinib versus rituximab in relapsed or refractory marginal zone lymphoma (MZL). Logistic propensity score models were used to estimate weights for the patient-level data from two phase II single-arm trials, MAGNOLIA and BGB-3111-AU-003, such that their characteristics matched the ibrutinib and rituximab aggregate-level data from PCYC-1121 and CHRONOS-3, respectively. The base case model for each comparison incorporated four key prognostic factors: prior lines of therapy, MZL subtype, response to prior therapy, and age. A sensitivity analysis incorporating additional prognostic factors was also conducted for the ibrutinib comparison. The impact of each covariate was explored a leave-one-out analysis. Compared with ibrutinib and rituximab, zanubrutinib demonstrated significant benefits in terms of both overall response and progression-free survival in patients with previously treated MZL.

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2024.2416577DOI Listing

Publication Analysis

Top Keywords

matching-adjusted indirect
8
indirect comparisons
8
magnolia bgb-3111-au-003
8
versus ibrutinib
8
marginal zone
8
zone lymphoma
8
zanubrutinib versus
8
ibrutinib rituximab
8
prognostic factors
8
ibrutinib
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!